Adipotide vs AOD9604: What’s the Difference?
The main difference between Adipotide and AOD9604 is mechanism: Adipotide is studied for targeted fat-cell apoptosis research — The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue. AOD9604 is studied for lipolysis without gh side-effects — Modified C-terminus fragment of HGH.
Vascular fat-targeting peptide vs GH-derived fragment.
Key differences between Adipotide and AOD9604
- •Mechanism: Adipotide — The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue. AOD9604 — Modified C-terminus fragment of HGH.
- •Primary research focus: Adipotide is studied for targeted fat-cell apoptosis research; AOD9604 is studied for lipolysis without gh side-effects.
- •Overlap: the two compounds share weight loss & metabolism.
- •Discussion context: Adipotide is most often discussed alongside targeted fat-cell apoptosis research, while AOD9604 centres on lipolysis without gh side-effects.
| Attribute | Adipotide FTPP | AOD9604 Anti-Obesity Drug 9604 |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Targeted fat-cell apoptosis research | Lipolysis without GH side-effects |
| Mechanism of action | The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue. | Modified C-terminus fragment of HGH. Stimulates lipolysis without affecting blood sugar or IGF-1. |
| Human research | Not catalogued | Strong |
| Animal research | Not catalogued | Strong |
| Mechanistic research | Not catalogued | Established |
| Study cadence cited | — | Daily, typically AM fasted |
| In plain English | It's designed to find the blood vessels feeding fat tissue and shut them down. | AOD9604 isolates the fat-burning effect of growth hormone without the muscle-building or blood-sugar effects. |
| How it works | The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue. | Stimulates lipolysis and inhibits lipogenesis without significant effect on IGF-1, insulin sensitivity, or glucose. |
| Researchers study | Obesity models in primates; documented rapid fat loss with renal-toxicity concerns. | Obesity, body composition, and osteoarthritis (intra-articular use). |
| Internet discussion | Discussed as the 'kills fat cells' peptide; almost always paired with strong warnings about kidney signals. | Discussed for targeted fat loss. |
Mechanism and research evidence, side by side
How Adipotide and AOD9604 differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
AOD9604
Modified C-terminus fragment of HGH. Stimulates lipolysis without affecting blood sugar or IGF-1.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Strong
- Animal research
- Strong
- Mechanistic research
- Established
Fat loss without affecting blood sugar or growth hormone axis
Adipotide
Targeted fat-cell apoptosis research
It's designed to find the blood vessels feeding fat tissue and shut them down.
The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue.
Obesity models in primates; documented rapid fat loss with renal-toxicity concerns.
Discussed as the 'kills fat cells' peptide; almost always paired with strong warnings about kidney signals.
Adipotide is an experimental peptide researched for targeted destruction of fat-tissue blood supply.
AOD9604
Lipolysis without GH side-effects
AOD9604 isolates the fat-burning effect of growth hormone without the muscle-building or blood-sugar effects.
Stimulates lipolysis and inhibits lipogenesis without significant effect on IGF-1, insulin sensitivity, or glucose.
Obesity, body composition, and osteoarthritis (intra-articular use).
Discussed for targeted fat loss.
AOD9604 is an hGH fragment researched for fat-burning effects without anabolic side effects.